Interpretation Training Program for Head and Neck Squamous Cell Carcinoma (HNSCC):
PD-L1 IHC 22C3 pharmDx
Are you ready to assess PD-L1 expression in Head and Neck Squamous Cell Carcinoma (HNSCC)?
PD-L1 testing provides a direct assessment of PD-L1 expression, which is a biomarker for response to anti-PD-1 therapy in HNSCC. Get educated on how to evaluate and score PD‑L1 expression in HNSCC using PD‑L1 IHC 22C3 pharmDx.
The PD-L1 IHC 22C3 pharmDx HNSCC Interpretation Training Program provides education that may help you accurately evaluate and score PD‑L1 expression in patients with HNSCC.
The PD-L1 IHC 22C3 pharmDx Interpretation Training Program uses in-depth content, engaging activities, and comprehensive cases to help you confidently:
- Understand the core principles of PD-L1 pathology
- Learn the process for evaluating stained specimens for PD-L1 expression
- Recognize confounding considerations that affect PD-L1 scoring
- Score specimens for PD-L1 expression across a variety of patient samples
1. PD-L1 IHC 22C3 pharmDx [package insert]. Carpinteria, CA: Dako, Agilent Pathology Solutions; 2019.
Review the PD-L1 IHC 22C3 pharmDx Intended Use